Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

GlaxoSmithKline stories

Apr 12, 2026

Two-Antibody Cocktail Developed to Combat Drug-Resistant RSV

Chinese scientists have developed a two-antibody cocktail for respiratory syncytial virus that prevented drug resistance in laboratory studies, addressing a persistent problem in RSV treatment.

Apr 12, 2026·1 source
00

Top claims

  • ▪Respiratory syncytial virus (RSV) is a seasonal infection that circulates globally
  • ▪Infants are among the most vulnerable to respiratory syncytial virus (RSV)
  • ▪GlaxoSmithKline's Arexvy is a respiratory syncytial virus (RSV) vaccine available for people who are 65 and older

Topics

Infectious Disease and OutbreaksDrug Approval and Clinical Trials

Related entities

PfizerChina